Rowan Chapman
Non Executive Director at Cambridge Innovation Capital
San Francisco Bay Area
Overview
Work Experience
Adjunct Lecturer, BioEngineering
2023 - Current
Non Executive Director
2022
A leading venture investor in Cambridge backing and building category-leading deep tech and life sciences companies.
Co-Founder
2023
Investing in early stage companies at the intersection of science, engineering, and computation.
Board Member
2023
Building a completely new way to quickly structure, standardize, and clean healthcare and clinical data using AI.
Cornerstone AI provides the cleaning and standardizing of data and too analyzing it.
Raised $10,000,000.00 from Healthy Ventures, Acrew Capital, Arif Nathoo, Travis May, Web Sun, Initiate Studios, Healthy Ventures and Initiate Studios.
Board Member
2021
An automated platform to enable a richer understanding of individual cell behaviors, interactions, and functions across a range of stimuli and parameters, at massively parallel scale.
Cellanome engages in cutting-edge synthetic biology and informatics methods through its multi-omics platform.
Raised $213,714,701.00 from PremjiInvest.
Board Member (NTRA)
2019
Committees: Chair Compensation, Member Audit Natera® is a worldwide genetic testing and diagnostics company that’s changing how doctors and patients manage genetic disease. Our team includes clinicians, scientists, biostatisticians, researchers, and talented laboratory professionals from around the globe.
Co-Founder, Advisor
2020
Initiate partners with entrepreneurs to launch innovative companies built on bold ideas. We focus at the intersections of healthcare, life sciences and technology. Founder success is our success.
Board Member
2014 - 2024
Independent board member Committees: Chair Compensation, Member Audit Evidation Health seeks to improve health outcomes through clinically and economically beneficial digital health solutions and new approaches to predictive analytics.
We enable and empower everyone to participate in better health outcomes.
Raised $259,000,000.00 from OMERS Private Equity, McKesson Ventures, B Capital and Kaiser Permanente Ventures.
Senior VP, Head of Innovation, Western North America, Australia & New Zealand
2017 - 2019
Led the J&J California team responsible for entrepreneurial ecosystem collaborations, deals and investments across Pharmaceutical, Medical Device and Consumer sectors. Drove deal structures including co-development, licensing, sponsored research and investment with negotiated terms ranging to >$1B.
Johnson & Johnson is a healthcare provider, expertise in innovative medicine and MedTech for every patient & for everyone.
Board Member
2015 - 2018
Initially CEO, then board member. Acquired by Thorne (THRN) Drawbridge Health is focused on enabling personal diagnostic testing – anytime, anywhere with a people-friendly system for collecting and stabilizing blood samples
Drawbridge Health helps doctor’s offices and clinics to collect blood samples for testing on site with a handheld device.